Nonalcoholic Steatohepatitis (NASH) Treatment Market

Key Highlights of the Report

The global nonalcoholic steatohepatitis (NASH) treatment market is segmented by drug type, end-use, and region. Vitamin E & pioglitazone is the leading segment by drug type, followed by obeticholic acid (OCA) and other drug types. In terms of end-use category, hospital pharmacies dominate the global market, with retail & specialty pharmacies and online pharmacies also playing a significant role, with North America as the leading region.

The global nonalcoholic steatohepatitis (NASH) treatment market is experiencing rapid growth driven by factors such as the increasing prevalence of NASH, raising awareness about the disease, and growing demand for effective treatment options. Developing novel therapies and drugs, advancements in diagnostic technologies, and favorable government initiatives are also driving market expansion. However, the market faces certain restraints, such as the need for approved drugs specifically for NASH, the high cost of treatment, and the complexity of clinical trial design for NASH therapies.

Nonetheless, there are considerable prospects in the global nonalcoholic steatohepatitis (NASH) treatment market, including discovering novel therapeutic molecules, increased R&D activities, and collaborations between pharmaceutical companies and research institutes. Moreover, the increased emphasis on early diagnosis and intervention and expanding healthcare access in emerging nations present further growth opportunities for the global NASH treatment market.

Market Overview

The global nonalcoholic steatohepatitis (NASH) treatment market has witnessed rapid growth and is estimated to grow at a CAGR of 62.9% between 2023 and 2030. The market was valued at USD 2.2 billion in 2022 and is expected to reach USD 66.96 billion in 2030.

What Are The Main Drivers Of The Global Nonalcoholic Steatohepatitis (NASH) Treatment Market?

The increasing prevalence of NASH worldwide, rising awareness and diagnosis of the disease, rising demand for effective treatment options, advancements in drug development and therapeutic approaches, and supportive government initiatives and funding for NASH research and development are the primary drivers of the nonalcoholic steatohepatitis (NASH) treatment market growth. The growing patient pool, lifestyle changes that increase NASH risk factors, and the need to better manage NASH-related consequences contribute to global market expansion.

What Are The Major Challenges Faced By The Global Nonalcoholic Steatohepatitis (NASH) Treatment Market?

The complexity of NASH diagnosis, limited availability of specific FDA-approved medications, high treatment costs, limited reimbursement policies, and shifting regulatory requirements are the primary challenges facing the global nonalcoholic steatohepatitis (NASH) treatment market.

What Are The Growth Opportunities In The Global Nonalcoholic Steatohepatitis (NASH) Treatment Market?

The global nonalcoholic steatohepatitis (NASH) treatment market has several growth opportunities, including the development of novel therapeutic agents targeting NASH, increased research and clinical trials for NASH treatment options, increased awareness of NASH among healthcare professionals and patients, and collaborations between pharmaceutical companies and research institutions to advance NASH therapies.

Executive Summary

Overview of the Global Nonalcoholic Steatohepatitis (NASH) Treatment Market

The global nonalcoholic steatohepatitis (NASH) treatment market is expanding rapidly due to the increasing prevalence of NASH caused by lifestyle changes, obesity, and metabolic diseases. NASH is a progressive liver disease with severe consequences such as cirrhosis and liver failure. As a result, there is an increasing need for effective therapeutic solutions. The market is characterized by the development of novel NASH-targeting medications and therapies, including antifibrotic agents, metabolic regulators, and immunotherapies. Furthermore, increased R&D investments, collaborations between pharmaceutical companies and research institutes, and implementation of favorable reimbursement policies all contribute to global market growth.

Market Definition

NASH is a progressive liver disease characterized by fat accumulation in the liver, inflammation, and liver cell destruction. It is most commonly related to obesity, insulin resistance, and metabolic disorders. The market includes a variety of therapy modalities, such as lifestyle changes, pharmaceutical therapies, and surgical procedures, all aimed at addressing the underlying causes and managing the symptoms of NASH. The market also comprises diagnostic tools and technology for detecting and monitoring NASH.

Market Insights

• The global demand for nonalcoholic steatohepatitis (NASH) treatment was valued at USD 2.2 Billion in 2022 and is expected to reach USD 66.96 Billion in 2030, growing at a CAGR of 62.9% between 2023 and 2030.
• Among the different drug types, vitamin E and pioglitazone currently dominate the market, with a share of over 62% in 2022, while the obeticholic acid (OCA) segment is expected to exhibit the fastest growth during the forecast period.
• Hospital pharmacies hold the largest market share in the distribution channels for NASH treatment, accounting for over 58% in 2022, and are expected to grow at a high CAGR.
• North America dominates the global nonalcoholic steatohepatitis (NASH) treatment market, accounting for a significant market share of over 40% in 2022.
• The Asia-Pacific region, particularly China and India, is anticipated to be the fastest-growing market for NASH treatment, presenting significant growth opportunities in the coming years.

Segmentation by Drug Type

• The vitamin E & pioglitazone segment dominates the global nonalcoholic steatohepatitis (NASH) treatment market, accounting for over 62% of the market share in terms of value in 2022.
• The obeticholic acid (OCA) segment is projected to exhibit the fastest market CAGR in the forecast period.
• Other drug types, including lanifibranor, semaglutide, resmetirom, and aramchol, also contribute to the demand for NASH treatment.

Segmentation by End-Use

• The retail & specialty pharmacies segment is expected to show the highest CAGR during the projected period.
• The hospital pharmacies segment currently holds the largest market share, accounting for over 58% of the market in 2022.

Segmentation by Region

• North America holds a significant share of the global NASH treatment market, accounting for approximately 40% in 2022.
• Europe is another prominent region in the global NASH treatment market, contributing to the overall market share.
• The Asia-Pacific region, particularly India and China, is expected to witness substantial growth in the NASH treatment market owing to the emerging prevalence of NASH and increasing healthcare spending.
• The rest of the world, including the Middle East, Latin America, and Africa, also contributes to the demand for NASH treatment, completing the market’s revenue share.

The global nonalcoholic steatohepatitis (NASH) treatment market is driven by several factors, including the increasing prevalence of NASH globally, the rising healthcare expenditure, and the growing awareness and diagnosis of the disease. However, challenges such as a lack of approved drugs, high treatment costs, and complex clinical trial design hinder market growth.

The United States holds a prominent position in the global NASH treatment market. The country exhibits a high prevalence of NASH cases due to the increasing incidence of obesity and metabolic disorders. The U.S. has favorable conditions for discovering and commercializing NASH therapeutic solutions owing to its well-established healthcare infrastructure and superior medical facilities. The existence of major pharmaceutical companies engaged in NASH R&D efforts leads to market expansion. Moreover, the U.S. has a robust regulatory framework and reimbursement procedures that support NASH therapy drug market access.

Japan is another key country in the nonalcoholic steatohepatitis (NASH) treatment industry, with a high market CAGR. The country faces a considerable NASH burden due to an aging population, a high prevalence of metabolic disorders, and lifestyle-related diseases. Japan strongly focuses on research and development in the field of NASH treatment, with a particular emphasis on innovative therapies and precision medicine. Japan’s regulatory environment supports expedited approval processes and fast-track designations for promising NASH treatments.

Increasing Prevalence of NASH

According to the American Liver Foundation, NASH is becoming a leading cause of liver transplantation in the United States, affecting approximately 25% of the population. The rising prevalence of NASH globally can be attributed to sedentary lifestyles, obesity, and metabolic disorders. As per the Global Liver Institute, approximately 25-30% of people globally have NAFLD, and nearly 2-6% have NASH, potentially increasing by more than 50% by 2030. This growing burden of NASH has created a significant demand for effective treatment options, driving the growth of the NASH treatment market.

Rise in Diabetic and Obese Population Across the Globe

Another factor boosting the global non-alcoholic steatohepatitis (NASH) therapies and diagnostics market is the growing diabetic and obese population. Patients with both NASH and diabetes, for example, have a higher risk of liver-related and non-liver-related illness and early death than those without liver disease. NASH is also linked to the obesity trifecta. According to the Global Liver Institute, diabetes affected approximately 9.3% of the global population (463 million people) in 2019 and is expected to rise by 25% by 2030 and 51% by 2045.

Lack of Advancements in the Therapeutic Field

Currently, there is no FDA-approved pharmacological treatment specifically for NASH. Although various drugs are being investigated in clinical trials, the lack of adequate and targeted therapies poses a significant challenge in managing NASH. It has been observed that a rising number of people globally are being diagnosed with NAFLD and NASH each year, and the only primary method of treatment is weight loss. It has also been observed that after almost 35 years of its formal description and 15 years of intense study from researchers across the globe, there is still no approved drug for the treatment of NASH.

High Development Costs and Regulatory Barriers

Developing new drugs and therapies for NASH involves extensive research, preclinical studies, and clinical trials, which incur substantial costs. Besides, the regulatory approval process for NASH treatments is rigorous, requiring robust clinical evidence of safety and efficacy. These factors contribute to the high development costs and lengthy timelines for bringing new NASH treatments to market. The financial burden and regulatory complexities act as restraints, potentially impeding the entry of new players and limiting the availability of treatment options for patients.

Emerging Pipeline of NASH Therapies

Several pharmaceutical companies are actively engaged in clinical trials, exploring various therapeutic targets and mechanisms of action. The potential approval of novel drugs targeting NASH could revolutionize the treatment landscape and offer new patient options. For example, in May 2022, Pfizer Inc reported that U.S. FDA granted Fast Track designation to Pfizer’s investigational combination (ervogastat/clesacostat) therapy for treating NASH. The Fast Track designation from the FDA reinforces Pfizer’s belief in ervogastat/clesacostat as a potential treatment for NASH, a severe and progressive liver disease with no currently approved therapies.

Competitive Landscape

Key Players

The global nonalcoholic steatohepatitis (NASH) treatment market is highly competitive and characterized by several key players. Some of the leading players in the global market and their market share are as follows:

• Intercept Pharmaceuticals
• Galmed Pharmaceuticals
• Inventiva Pharma
• AbbVie Inc
• Galectin Therapeutics Inc
• Madrigal Pharmaceuticals
• NGM Biopharmaceuticals Inc
• Novo Nordisk A/S
• Bristol Myers Squibb
• Gilead Sciences Inc

These companies are actively involved in R&D activities to introduce innovative and effective treatment options for NASH. These companies are developing NASH-specific therapies, conducting clinical trials, and seeking regulatory approvals. Moreover, partnerships, collaborations, and acquisitions are common strategies key market players adopt to expand their market presence and strengthen their product portfolios.

For example, Gilead Sciences Inc announced a strategic agreement with Insitro in April 2019 to discover innovative medicines for non-alcoholic steatohepatitis. Gilead Sciences Inc will use Insitro’s unique platform for medication development as part of this agreement.

Likewise, Intercept Pharmaceuticals Inc reported favorable results from its pivotal Phase 3 REGENERATE study of obeticholic acid (OCA) in patients with non-alcoholic steatohepatitis (NASH) liver fibrosis in February 2019.

Summary of Key Findings

• The rising incidence of risk factors such as obesity, diabetes, and sedentary lifestyles contribute to the growing prevalence of NASH, driving the demand for effective treatment options.
• Market segmented by drug type, end-use, and region.
• Vitamin E and pioglitazone are the leading drug types, accounting for over 62% market share in 2022, while obeticholic acid (OCA) is expected to exhibit the fastest growth rate.
• North America is the largest regional market for NASH treatment, with a significant market revenue share.
• Europe also holds a substantial market share, while the Asia-Pacific region, particularly China and India, is expected to witness rapid growth.
• Higher treatment costs, limited availability of approved therapies, and the complex nature of NASH pose challenges to global market growth.

Future Outlook

• The increasing focus on early diagnosis and screening programs for NASH and advancements in diagnostic technologies fuel the demand for NASH treatment.
• Introducing novel drug candidates and pipeline therapies targeting NASH, such as farnesoid X receptor (FXR) agonists and apoptosis signal-regulating kinase 1 (ASK1) inhibitors, provides promising market growth opportunities.
• Government initiatives and healthcare reforms to improve NASH awareness, diagnosis, and treatment access further drive market growth.

Segmentation

• By Drug Type
  • Vitamin E & Pioglitazone
  • Obeticholic Acid (OCA)
  • Lanifibranor
  • Semaglutide
  • Resmetirom
  • Aramchol
  • Others
• By End-Use
  • Hospital Pharmacies
  • Retail & Specialty Pharmacies
  • Others
• By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • The U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Data Modelling
1.3.2.1. Company Share Analysis Model
1.3.2.2. Revenue-Based Modelling
1.3.3. Phase III – Primary Research
1.3.4. Research Limitations
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
2.2. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By End-Use
2.3. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Drug Type
2.4. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Value, 2017-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Driver 1
3.2.1.2. Driver 2
3.2.1.3. Driver 3
3.2.2. Market Restraints
3.2.2.1. Restraint 1
3.2.2.2. Restraint 2
3.2.3. Market Opportunities
3.2.3.1. Opportunity 1
3.2.3.2. Opportunity 2
3.2.4. Major Industry Challenges
3.2.4.1. Challenge 1
3.2.4.2. Challenge 2
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. End-Use
3.5.2. Drug Type
3.5.3. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Technology Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company Market Share of Key Players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By End-Use
7.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Overview, by End-Use
7.1.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Revenue Share, By End-Use, 2022 Vs 2030 (in %)
7.2. Hospital Pharmacies
7.2.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Region, 2017-2030 (US$ Bn)
7.3. Retail & Specialty Pharmacies
7.3.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Region, 2017-2030 (US$ Bn)
7.4. Others
7.4.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Region, 2017-2030 (US$ Bn)

8. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Drug Type
8.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Overview, by Drug Type
8.1.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Drug Type, 2022 vs 2030 (in %)
8.2. Vitamin E & Pioglitazone
8.2.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Region, 2017-2030 (US$ Bn)
8.3. Obeticholic Acid (OCA)
8.3.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Region, 2017-2030 (US$ Bn)
8.4. Lanifibranor
8.4.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Region, 2017-2030 (US$ Bn)
8.5. Semaglutide
8.5.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Region, 2017-2030 (US$ Bn)
8.6. Resmetirom
8.6.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Region, 2017-2030 (US$ Bn)
8.7. Aramchol
8.7.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Region, 2017-2030 (US$ Bn)
8.8. Others
8.8.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Region, 2017-2030 (US$ Bn)

9. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Region
9.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Overview, by Region
9.1.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Region, 2022 vs 2030 (in%)
9.2. End-Use
9.2.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By End-Use, 2017-2030 (US$ Bn)
9.3. Drug Type
9.3.1. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, By Drug Type, 2017-2030 (US$ Bn)

10. North America Nonalcoholic Steatohepatitis (NASH) Treatment Market Analysis
10.1. North America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2030(US$ Bn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. North America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2030(US$ Bn)
10.2.1. Overview
10.2.2. SRC Analysis
10.3. North America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Country, 2017-2030 (US$ Bn)
10.3.1. North America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Country, 2022 Vs 2030 (in%)
10.3.2. U.S.
10.3.2.1. U.S. Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.2.2. U.S. Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
10.3.2.3. U.S. Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)
10.3.3. Canada
10.3.3.1. Canada Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.3.2. Canada Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
10.3.3.3. Canada Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)
10.3.4. Mexico
10.3.4.1. Mexico Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.4.2. Mexico Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
10.3.4.3. Mexico Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)

11. Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market Analysis
11.1. Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2030(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2030(US$ Bn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Country, 2017-2030 (US$ Bn)
11.3.1. Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Country, 2022 Vs 2030 (in%)
11.3.2. Germany
11.3.2.1. Germany Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.2.2. Germany Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
11.3.2.3. Germany Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)
11.3.3. France
11.3.3.1. France Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.3.2. France Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
11.3.3.3. France Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)
11.3.4. UK
11.3.4.1. UK Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.4.2. UK Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
11.3.4.3. UK Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)
11.3.5. Italy
11.3.5.1. Italy Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.5.2. Italy Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
11.3.5.3. Italy Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)
11.3.6. Spain
11.3.6.1. Spain Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.6.2. Spain Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
11.3.6.3. Spain Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)
11.3.7. Rest of Europe
11.3.7.1. Rest of Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.7.2. Rest of Europe Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
11.3.7.3. Rest of Europe Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)

12. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market Analysis
12.1. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2030(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2030(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Country, 2017-2030 (US$ Bn)
12.3.1. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Country, 2022 Vs 2030 (in%)
12.3.2. China
12.3.2.1. China Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.2.2. China Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
12.3.2.3. China Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)
12.3.3. Japan
12.3.3.1. Japan Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.3.2. Japan Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
12.3.3.3. Japan Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)
12.3.4. India
12.3.4.1. India Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.4.2. India Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
12.3.4.3. India Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)
12.3.5. South Korea
12.3.5.1. South Korea Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.5.2. South Korea Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
12.3.5.3. South Korea Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)
12.3.6. South-East Asia
12.3.6.1. South-East Asia Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.6.2. South-East Asia Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
12.3.6.3. South-East Asia Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)
12.3.7. Rest of Asia Pacific
12.3.7.1. Rest of Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.7.2. Rest of Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
12.3.7.3. Rest of Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)

13. Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market Analysis
13.1. Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2030(US$ Bn)
13.1.1. Overview
13.1.2. SRC Analysis
13.2. Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2030(US$ Bn)
13.2.1. Overview
13.2.2. SRC Analysis
13.3. Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Country, 2017-2030 (US$ Bn)
13.3.1. Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Country, 2022 Vs 2030 (in%)
13.3.2. Brazil
13.3.2.1. Brazil Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.2.2. Brazil Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
13.3.2.3. Brazil Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)
13.3.3. Argentina
13.3.3.1. Argentina Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.3.2. Argentina Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
13.3.3.3. Argentina Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)
13.3.4. Rest of Latin America
13.3.4.1. Rest of Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.4.2. Rest of Latin America Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
13.3.4.3. Rest of Latin America Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)

14. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market Analysis
14.1. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2030(US$ Bn)
14.1.1. Overview
14.1.2. SRC Analysis
14.2. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2030(US$ Bn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Country, 2017-2030 (US$ Bn)
14.3.1. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Country, 2022 Vs 2030 (in%)
14.3.2. GCC Countries
14.3.2.1. GCC Countries Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.2.2. GCC Countries Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
14.3.2.3. GCC Countries Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)
14.3.3. South Africa
14.3.3.1. South Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.3.2. South Africa Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
14.3.3.3. South Africa Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)
14.3.4. Rest of Middle East and Africa
14.3.4.1. Rest of Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.4.2. Rest of Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment, By End-Use, 2017-2030 (US$ Bn)
14.3.4.3. Rest of Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment, By Drug Type, 2017-2030 (US$ Bn)

15. Company Profiles
15.1. Intercept Pharmaceuticals
15.1.1. Company Overview
15.1.2. Products/Services Portfolio
15.1.3. Geographical Presence
15.1.4. Financial Summary
15.1.4.1. Market Revenue and Net Profit (2019-2022)
15.1.4.2. Business Segment Revenue Analysis
15.1.4.3. Geographical Revenue Analysis
15.2. Galmed Pharmaceuticals
15.3. Inventiva Pharma
15.4. AbbVie Inc
15.5. Galectin Therapeutics Inc
15.6. Madrigal Pharmaceuticals
15.7. NGM Biopharmaceuticals Inc
15.8. Novo Nordisk A/S
15.9. Bristol Myers Squibb
15.10. Gilead Sciences Inc

List of Figures
FIG. 1 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom Up Approach
FIG. 3 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Segmentation
FIG. 4 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2022 (US$ Bn)
FIG. 5 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2022 (US$ Bn)
FIG. 6 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Geography, 2022 (US$ Bn)
FIG. 7 Attractive Investment Proposition, by End-Use, 2022
FIG. 8 Attractive Investment Proposition, by Drug Type, 2022
FIG. 9 Attractive Investment Proposition, by Geography, 2022
FIG. 10 Global Market Share Analysis of Key Nonalcoholic Steatohepatitis (NASH) Treatment Market Manufacturers, 2022
FIG. 11 Global Market Positioning of Key Nonalcoholic Steatohepatitis (NASH) Treatment Market Manufacturers, 2022
FIG. 12 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Value Contribution, By End-Use, 2022 & 2030 (Value %)
FIG. 13 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Hospital Pharmacies, Value, 2017-2030 (US$ Bn)
FIG. 14 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Retail & Specialty Pharmacies, Value, 2017-2030 (US$ Bn)
FIG. 15 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Others, Value, 2017-2030 (US$ Bn)
FIG. 16 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Value Contribution, By Drug Type, 2022 & 2030 (Value %)
FIG. 17 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Vitamin E & Pioglitazone, Value, 2017-2030 (US$ Bn)
FIG. 18 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Obeticholic Acid (OCA), 2017-2030 (US$ Bn)
FIG. 19 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Lanifibranor, Value, 2017-2030 (US$ Bn)
FIG. 20 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Semaglutide, 2017-2030 (US$ Bn)
FIG. 21 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Resmetirom, Value, 2017-2030 (US$ Bn)
FIG. 22 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Aramchol, 2017-2030 (US$ Bn)
FIG. 23 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Others, Value, 2017-2030 (US$ Bn)
FIG. 24 North America Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 25 U.S. Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 26 Canada Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 27 Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 28 Germany Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 29 France Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 30 U.K. Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 31 Italy Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 32 Spain Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 33 Rest of Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 34 Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 35 China Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 36 Japan Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 37 India Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 38 South Korea Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 39 South-East Asia Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 40 Rest of Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 41 Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 42 Brazil Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 43 Mexico Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 44 Rest of Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 45 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 46 GCC Countries Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 47 South Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)
FIG. 48 Rest of Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, 2017-2030 (US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Nonalcoholic Steatohepatitis (NASH) Treatment Market
TABLE 2 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market: Market Drivers Impact Analysis
TABLE 3 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market: Market Restraints Impact Analysis
TABLE 4 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Competitive Benchmarking, 2022
TABLE 5 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Key Strategies Analysis, 2022
TABLE 7 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Hospital Pharmacies, By Region, 2017-2022 (US$ Bn)
TABLE 8 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Hospital Pharmacies, By Region, 2023-2030 (US$ Bn)
TABLE 9 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Retail & Specialty Pharmacies, By Region, 2017-2022 (US$ Bn)
TABLE 10 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Retail & Specialty Pharmacies, By Region, 2023-2030 (US$ Bn)
TABLE 11 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Others, By Region, 2017-2022 (US$ Bn)
TABLE 12 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Others, By Region, 2023-2030 (US$ Bn)
TABLE 13 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Vitamin E & Pioglitazone, By Region, 2017-2022 (US$ Bn)
TABLE 14 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Vitamin E & Pioglitazone, By Region, 2023-2030 (US$ Bn)
TABLE 15 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Obeticholic Acid (OCA), By Region, 2017-2022 (US$ Bn)
TABLE 16 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Obeticholic Acid (OCA), By Region, 2023-2030 (US$ Bn)
TABLE 17 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Lanifibranor, By Region, 2017-2022 (US$ Bn)
TABLE 18 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Lanifibranor, By Region, 2023-2030 (US$ Bn)
TABLE 19 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Semaglutide, By Region, 2017-2022 (US$ Bn)
TABLE 20 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Semaglutide, By Region, 2023-2030 (US$ Bn)
TABLE 21 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Resmetirom, By Region, 2017-2022 (US$ Bn)
TABLE 22 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Resmetirom, By Region, 2023-2030 (US$ Bn)
TABLE 23 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Aramchol, By Region, 2017-2022 (US$ Bn)
TABLE 24 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Aramchol, By Region, 2023-2030 (US$ Bn)
TABLE 25 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Others, By Region, 2017-2022 (US$ Bn)
TABLE 26 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Others, By Region, 2023-2030 (US$ Bn)
TABLE 27 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 28 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 29 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 30 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 31 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Region, 2017-2022 (US$ Bn)
TABLE 32 Global Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Region, 2023-2030 (US$ Bn)
TABLE 33 North America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 34 North America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 35 North America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 36 North America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 37 North America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Country, 2017-2022 (US$ Bn)
TABLE 38 North America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Country, 2023-2030 (US$ Bn)
TABLE 39 United States Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 40 United States Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 41 United States Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 42 United States Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 43 Canada Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 44 Canada Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 45 Canada Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 46 Canada Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 47 Mexico Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 48 Mexico Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 49 Mexico Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 50 Mexico Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 51 Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 52 Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 53 Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 54 Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 55 Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Country, 2017-2022 (US$ Bn)
TABLE 56 Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Country, 2023-2030 (US$ Bn)
TABLE 57 Germany Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 58 Germany Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 59 Germany Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 60 Germany Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 61 France Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 62 France Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 63 France Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 64 France Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 65 United Kingdom Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 66 United Kingdom Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 67 United Kingdom Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 68 United Kingdom Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 69 Italy Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 70 Italy Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 71 Italy Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 72 Italy Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 73 Spain Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 74 Spain Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 75 Spain Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 76 Spain Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 77 Rest of Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 78 Rest of Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 79 Rest of Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 80 Rest of Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 81 Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 82 Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 83 Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 84 Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 85 China Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 86 China Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 87 China Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 88 China Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 89 Japan Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 90 Japan Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 91 Japan Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 92 Japan Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 93 India Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 94 India Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 95 India Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 96 India Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 97 South Korea Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 98 South Korea Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 99 South Korea Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 100 South Korea Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 101 South-East Asia Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 102 South-East Asia Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 103 South-East Asia Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 104 South-East Asia Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 105 Rest of Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 106 Rest of Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 107 Rest of Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 108 Rest of Asia Pacific Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 109 Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 110 Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 111 Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 112 Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 113 Brazil Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 114 Brazil Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 115 Brazil Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 116 Brazil Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 117 Argentina Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 118 Argentina Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 119 Argentina Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 120 Argentina Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 121 Rest of Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 122 Rest of Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 123 Rest of Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 124 Rest of Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 125 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 126 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 127 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 128 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 129 GCC Countries Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 130 GCC Countries Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 131 GCC Countries Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 132 GCC Countries Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 133 South Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 134 South Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 135 South Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 136 South Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)
TABLE 137 Rest of Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2017-2022 (US$ Bn)
TABLE 138 Rest of Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, by End-Use, 2023-2030 (US$ Bn)
TABLE 139 Rest of Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2017-2022 (US$ Bn)
TABLE 140 Rest of Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Treatment Market, by Drug Type, 2023-2030 (US$ Bn)